KFH - ANTIOCH
- Type
- Teaching hospital
- Where
- ANTIOCH, CA
- Medicare CCN
- 050760
- Received
- $5,633,777 in 241 records, 2020 ($0 general, $5,633,777 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | Research payment | 241 | $5,633,777 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 240 | $5,624,567 | 2020 |
| MEDIVATION LLC. | 1 | $9,210 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 241 | $5,633,777 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-29 | PFIZER INC. | $34,099 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-29 | PFIZER INC. | $28,343 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-25 | PFIZER INC. | $17,057 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-19 | PFIZER INC. | $82,943 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-18 | PFIZER INC. | $4,332 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-16 | PFIZER INC. | $60,193 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-16 | PFIZER INC. | $3,962 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA | 2020 | |
| 2020-12-14 | PFIZER INC. | $560 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-12-12 | PFIZER INC. | $38,787 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-12 | PFIZER INC. | $30,197 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-10 | PFIZER INC. | $148,707 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-12-05 | PFIZER INC. | $41,680 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-05 | PFIZER INC. | $41,078 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-04 | PFIZER INC. | $9,580 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-04 | PFIZER INC. | $1,642 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-12-03 | PFIZER INC. | $1,981 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA | 2020 | |
| 2020-12-03 | PFIZER INC. | $1,710 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-12-03 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 | |
| 2020-12-03 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 | |
| 2020-12-02 | PFIZER INC. | $4,969 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-12-01 | PFIZER INC. | $32,850 | Research payment | Cash or cash equivalent | CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES | 2020 | |
| 2020-11-28 | PFIZER INC. | $32,128 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-28 | PFIZER INC. | $30,611 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-26 | PFIZER INC. | $25,901 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-21 | PFIZER INC. | $18,690 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-21 | PFIZER INC. | $10,656 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA | 2020 | |
| 2020-11-20 | PFIZER INC. | $15,931 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-20 | PFIZER INC. | $897 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-11-18 | PFIZER INC. | $30,509 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-18 | PFIZER INC. | $4,928 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-11-18 | PFIZER INC. | $1,619 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-11-17 | PFIZER INC. | $39,895 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-17 | PFIZER INC. | $35,183 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-14 | PFIZER INC. | $25,037 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-11 | PFIZER INC. | $28,421 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-07 | PFIZER INC. | $37,964 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-06 | PFIZER INC. | $50,346 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-05 | PFIZER INC. | $17,000 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-31 | PFIZER INC. | $44,181 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-31 | PFIZER INC. | $33,467 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-30 | PFIZER INC. | $39,010 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-30 | PFIZER INC. | $1,642 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-10-29 | PFIZER INC. | $2,607 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-10-28 | PFIZER INC. | $5,655 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-10-26 | MEDIVATION LLC. | $9,210 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE | 2020 |
| 2020-10-23 | PFIZER INC. | $118,813 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-23 | PFIZER INC. | $46,291 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-22 | PFIZER INC. | $45,188 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-16 | PFIZER INC. | $1,642 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-10-14 | PFIZER INC. | $57,552 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-10 | PFIZER INC. | $63,215 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-08 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-07 | PFIZER INC. | $50,570 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-06 | PFIZER INC. | $65,971 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-02 | PFIZER INC. | $147,864 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-02 | PFIZER INC. | $129,306 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-02 | PFIZER INC. | $4,262 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-10-01 | PFIZER INC. | $158,301 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $145,509 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $127,920 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $110,331 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $107,932 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $99,937 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-10-01 | PFIZER INC. | $58,395 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-01 | PFIZER INC. | $12,655 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-10-01 | PFIZER INC. | $2,037 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-09-28 | PFIZER INC. | $560 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-09-26 | PFIZER INC. | $116,577 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-26 | PFIZER INC. | $92,077 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-25 | PFIZER INC. | $49,824 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-19 | PFIZER INC. | $193,390 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-19 | PFIZER INC. | $116,959 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-19 | PFIZER INC. | $3,230 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-09-18 | PFIZER INC. | $86,713 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-18 | PFIZER INC. | $2,581 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-09-17 | PFIZER INC. | $871 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-09-12 | PFIZER INC. | $130,549 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-11 | PFIZER INC. | $69,979 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-10 | PFIZER INC. | $83,461 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-07 | PFIZER INC. | $15,956 | Research payment | Cash or cash equivalent | CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES | 2020 | |
| 2020-08-29 | PFIZER INC. | $80,932 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-08-29 | PFIZER INC. | $2,607 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-08-22 | PFIZER INC. | $20,233 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-08-19 | PFIZER INC. | $5,938 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-08-18 | PFIZER INC. | $5,359 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-08-13 | PFIZER INC. | $6,491 | Research payment | In-kind items and services | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-08-12 | PFIZER INC. | $2,375 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-08-10 | PFIZER INC. | $148,632 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-08-08 | PFIZER INC. | $10,175 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-07-31 | PFIZER INC. | $1,361 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-07-31 | PFIZER INC. | $1,066 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-07-31 | PFIZER INC. | $897 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-07-30 | PFIZER INC. | $3,500 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-07-29 | PFIZER INC. | $1,920 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-07-27 | PFIZER INC. | $74,712 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-07-23 | PFIZER INC. | $14,000 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-07-17 | PFIZER INC. | $4,183 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-07-17 | PFIZER INC. | $1,538 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-07-02 | PFIZER INC. | $215,260 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-07-02 | PFIZER INC. | $11,329 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-07-02 | PFIZER INC. | $3,068 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-06-25 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS | 2020 |
| 2020-06-24 | PFIZER INC. | $960 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-16 | PFIZER INC. | $5,798 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-06-15 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | CRCCONTINUATION OF ASSESSMENT OF THE IMPACT OF PREVNAR 13 13VPNC ON INVASIVE PNEUMOCOCCAL DISEASE CAUSED BY VACCINE SERO | 2020 |
| 2020-06-11 | PFIZER INC. | $9,177 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-06-11 | PFIZER INC. | $6,119 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-06-11 | PFIZER INC. | $5,189 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-06-11 | PFIZER INC. | $4,250 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-06-04 | PFIZER INC. | $128,602 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $71,098 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $66,373 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $66,317 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $56,575 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $50,145 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $47,861 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $44,173 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-06-04 | PFIZER INC. | $4,354 | Research payment | Cash or cash equivalent | TRUMENBA Biological, VACCINES | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA | 2020 |
| 2020-06-04 | PFIZER INC. | $960 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-29 | PFIZER INC. | $10,173 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-05-27 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-05-16 | PFIZER INC. | $4,237 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-05-15 | PFIZER INC. | $5,129 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-05-14 | PFIZER INC. | $10,806 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2020 |
| 2020-05-14 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | TRUMENBA Biological, VACCINES | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA | 2020 |
| 2020-05-14 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-05-14 | PFIZER INC. | $650 | Research payment | Cash or cash equivalent | TRUMENBA Biological, VACCINES | A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVA | 2020 |
| 2020-05-13 | PFIZER INC. | $5,050 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2020 |
| 2020-05-07 | PFIZER INC. | $8,400 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-05-07 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-05-07 | PFIZER INC. | $650 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-05-01 | PFIZER INC. | $8,267 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-05-01 | PFIZER INC. | $7,727 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-05-01 | PFIZER INC. | $5,540 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-05-01 | PFIZER INC. | $3,974 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-04-30 | PFIZER INC. | $5,571 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-04-30 | PFIZER INC. | $2,607 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-04-22 | PFIZER INC. | $3,889 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-04-22 | PFIZER INC. | $2,204 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $1,920 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $1,185 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-22 | PFIZER INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-21 | PFIZER INC. | $8,396 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-04-18 | PFIZER INC. | $2,607 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-04-13 | PFIZER INC. | $185,988 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-04-08 | PFIZER INC. | $2,880 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-08 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-04-08 | PFIZER INC. | $300 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-30 | PFIZER INC. | $148,632 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2020 |
| 2020-03-26 | PFIZER INC. | $3,260 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-26 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-26 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-26 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-19 | PFIZER INC. | $17,771 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-03-18 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-03-17 | PFIZER INC. | $1,022 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2020 |
| 2020-03-12 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $1,185 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-12 | PFIZER INC. | $250 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-05 | PFIZER INC. | $944 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-05 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-05 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-05 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-03-05 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-28 | PFIZER INC. | $11,858 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2020 |
| 2020-02-28 | PFIZER INC. | $8,650 | Research payment | Cash or cash equivalent | A LONGTERM OPEN LABEL EXTENSION STUDY OF PF06651600 FOR THE TREATMENT OF ALOPECIA AREATA | 2020 | |
| 2020-02-26 | PFIZER INC. | $3,304 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2020 | |
| 2020-02-25 | PFIZER INC. | $2,093 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-25 | PFIZER INC. | $1,256 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-25 | PFIZER INC. | $1,256 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-25 | PFIZER INC. | $837 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-25 | PFIZER INC. | $592 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-20 | PFIZER INC. | $4,090 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2020 |
| 2020-02-19 | PFIZER INC. | $4,723 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $3,853 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $1,889 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $1,574 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-19 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-13 | PFIZER INC. | $14,981 | Research payment | Cash or cash equivalent | LORBRENA Drug, ONCOLOGY | AN EXPANDED ACCESS PROTOCOL FOR LORLATINIB FOR TREATMENT OF PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING S | 2020 |
| 2020-02-13 | PFIZER INC. | $2,667 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-06 | PFIZER INC. | $2,093 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-02-06 | PFIZER INC. | $1,920 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-06 | PFIZER INC. | $1,778 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-02-06 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 |
The latest 200 records of 241.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Antioch, CA | County Contra Costa County, CA | State California |
|---|---|---|---|
| Population B01003 | 116,477 | 1,165,012 | 39,287,377 |
| Population, 2020 census P1 | 115,291 | 1,165,927 | 39,538,223 |
| Median age B01002 | 38.4 | 40.5 | 37.9 |
| Under 18 B01001 | 22.8% | 22.0% | 22.0% |
| 65 and over B01001 | 14.3% | 17.1% | 15.7% |
| Households B11001 | 37,381 | 414,417 | 13,548,091 |
| Foreign born B05002 | 24.6% | 26.6% | 27.0% |
| Median household income B19013 | $97,465 | $127,229 | $99,122 |
| Median family income B19113 | $109,115 | $148,679 | $113,346 |
| Per capita income B19301 | $41,008 | $62,927 | $49,513 |
| Poverty rate B17001 | 11.4% | 8.4% | 12.0% |
| Unemployment rate B23025 | 7.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 60,709 | 608,620 | 20,068,466 |
| Mean commute (minutes) B08013 | 42.0 | 35.3 | 28.7 |
| Bachelor's degree or higher B15003 | 23.9% | 45.2% | 37.1% |
| Housing units B25001 | 38,629 | 429,260 | 14,644,735 |
| Owner-occupied B25003 | 63.6% | 68.0% | 55.9% |
| Renters B25003 | 36.4% | 32.0% | 44.1% |
| Median home value B25077 | $629,700 | $866,800 | $734,700 |
| Median gross rent B25064 | $2,278 | $2,375 | $2,036 |
| White, not Hispanic B03002 | 23.4% | 38.1% | 33.8% |
| Black B03002 | 18.2% | 7.9% | 5.2% |
| Hispanic or Latino B03002 | 35.6% | 27.6% | 40.2% |
| Asian B03002 | 13.9% | 18.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.
Comments